Treatment of Hemophilia A Patients With FVIII Inhibitors

Condition:   Hemophilia A Interventions:   Biological: Nuwiq;   Biological: Octanate;   Biological: Wilate;   Biological: Emicizumab;   Biological: Recombinant factor VIIa (rFVIIa);   Biological: Activated prothrombin complex concentrate (aPCC) Sponsors:   Emory University;   Octapharma Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials